grn-1201
Vaccineexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2016 (NCT02696356)
Timeline
Indications
Mechanism of action
- Melanoma cellsImmunity, active
immunity, active - melanoma cells
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- grn-1201
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03417882 | Phase 2 | Jun 30, 2018 | BrightPath Biotherapeutics |
| NCT02696356 | Phase 1 | Apr 1, 2016 | BrightPath Biotherapeutics, Providence Health & Services |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BrightPath Biotherapeutics | For profit | 2 | 2 | 2 | 2016 |
| Providence Health & Services | Academic/Hospital | 1 | 0 | 1 | 2016 |
2 organizations
Page 1 / 1